374 related articles for article (PubMed ID: 29090600)
1. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.
Cai X; Gao X; Yang W; Ji L
Expert Opin Pharmacother; 2017 Dec; 18(17):1789-1798. PubMed ID: 29090600
[TBL] [Abstract][Full Text] [Related]
2. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
Komatsu M; Watada H; Kaneko S; Ross Agner BF; Nishida T; Kaku K
J Diabetes Investig; 2021 Sep; 12(9):1610-1618. PubMed ID: 33595901
[TBL] [Abstract][Full Text] [Related]
4. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
Risovic I; Dumanovic MS; Bojic M; Djekic D
BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
[TBL] [Abstract][Full Text] [Related]
6. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
[TBL] [Abstract][Full Text] [Related]
7. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
[TBL] [Abstract][Full Text] [Related]
8. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
[TBL] [Abstract][Full Text] [Related]
9. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
11. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
Philis-Tsimikas A; Billings LK; Busch R; Portillo CM; Sahay R; Halladin N; Eggert S; Begtrup K; Harris S
Diabetes Obes Metab; 2019 Jun; 21(6):1399-1408. PubMed ID: 30761720
[TBL] [Abstract][Full Text] [Related]
12. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
13. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
Adv Ther; 2017 Apr; 34(4):954-965. PubMed ID: 28281218
[TBL] [Abstract][Full Text] [Related]
15. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
Wang W; Agner BFR; Luo B; Liu L; Liu M; Peng Y; Qu S; Stachlewska KA; Wang G; Yuan G; Zhang Q; Ning G
J Diabetes; 2022 Jun; 14(6):401-413. PubMed ID: 35762390
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Home PD; Aroda VR; Blonde L; Guyot P; Shaunik A; Fazeli MS; Goswami H; Kalra S; Pourrahmat MM
Diabetes Obes Metab; 2020 Nov; 22(11):2170-2178. PubMed ID: 32627297
[TBL] [Abstract][Full Text] [Related]
17. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK; Agner BFR; Altuntas Y; Grøn R; Halladin N; Klonoff DC; Tentolouris N; Jódar E
J Diabetes Sci Technol; 2021 May; 15(3):636-645. PubMed ID: 32107930
[TBL] [Abstract][Full Text] [Related]
18. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
Pei Y; Agner BR; Luo B; Dong X; Li D; Liu J; Liu L; Liu M; Lu Y; Nishida T; Xu X; Mu Y
Diabetes Obes Metab; 2021 Dec; 23(12):2687-2696. PubMed ID: 34387411
[TBL] [Abstract][Full Text] [Related]
19. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
[TBL] [Abstract][Full Text] [Related]
20. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
Wilding JP; Bain SC
Diabet Med; 2016 Jul; 33(7):864-76. PubMed ID: 26525806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
